{"filings":[{"id":926927,"accession_number":"0001193125-26-262264","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2026-06-08T22:23:37+00:00","items":["5.07"],"status":"ready","headline":"AN2 Therapeutics stockholders elect three Class I directors and ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class I director nominees elected: Kabeer Aziz (13.5M for, 4.0M withheld), Gilbert Marks (15.9M for), Rob Readnour (15.9M for).","Ratification of PricewaterhouseCoopers as auditor for fiscal 2026 approved with 22,724,674 for, 13 against, 16,848 abstain.","Approximately 63.18% of outstanding shares (22.7M of 35.99M) represented at meeting, constituting quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861318,"accession_number":"0001193125-26-257430","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2026-06-04T20:15:49+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"AN2 Therapeutics reports 100% parasite elimination in NHP study; Phase 2 for Chagas planned late 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["28-day AN2-502998 treatment in NHPs with chronic T. cruzi infection achieved 100% parasite elimination at human-target exposures, durable for 4 months post-treatment.","Phase 1 FIH study (NCT07024589) in healthy volunteers showed favorable safety, no dose-limiting toxicities, and PK exposures at NHP efficacy thresholds.","Chagas disease affects ~300k in U.S. and ~10M globally; no FDA-approved treatments for adults with chronic disease.","Company plans to initiate Phase 2 proof-of-concept study late 2026; AN2-502998 eligible for FDA Tropical Disease Priority Review Voucher if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12923,"accession_number":"0001193125-26-216752","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2026-05-11T20:06:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics Q1 net loss $10.0M; progresses oral epetraborole to Phase 2 for PV","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.0M vs $10.6M in Q1 2025; R&D expenses $6.7M, down from $7.7M.","Cash and investments $85.3M as of Mar 31, 2026; raised $40M in March private placement; cash runway into 2029.","Oral epetraborole for polycythemia vera to enter Phase 2 in Q3 2026; data readouts expected from Q4 2026.","Phase 2 investigator-initiated trial for M. abscessus lung disease commenced in March 2026; topline results late 2027.","Chagas disease: Phase 1 trial completed dosing; Phase 1 and NHP efficacy data expected in Q2 2026."],"consensus_eps_estimate":-0.2346,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96511,"accession_number":"0001193125-26-149822","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AN2 Therapeutics enters $80M ATM offering with Jefferies; prior ATM terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into Open Market Sale Agreement with Jefferies to sell up to $80M of common stock at market prices.","Jefferies receives up to 3.0% commission; offering may be terminated by either party on 10 days' notice.","Terminated prior TD Cowen ATM under which 2,502,000 shares were sold for aggregate $20,016,251.","Effective April 9, 2026; no shares have been sold yet under new agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110489,"accession_number":"0001193125-26-117765","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AN2 Therapeutics reprices stock options to $3.91; original exercise price applies if exercised before Premium End Date","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved repricing of all outstanding options to $3.91 per share (closing price on March 19, 2026).","Repriced options subject to original exercise price if exercised before Premium End Date (Sept 19, 2027, change in control, or death/disability).","Named executive officers hold 1,106,764 total Eligible Options with original exercise prices ranging from $6.60 to $17.88.","CEO Eric Easom holds 742,649 repriced options; CFO Lucy Day holds 221,965; CLO/COO Joshua Eizen holds 142,150."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110488,"accession_number":"0001193125-26-110681","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports FY2025 net loss of $35.2M; $40M private placement extends runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025 was $35.2 million, compared to $51.3 million in FY2024.","Cash and investments at Dec 31, 2025: $60.0 million; private placement in March 2026 added ~$40 million gross.","Phase 2 study of oral epetraborole in polycythemia vera to begin 3Q26; data readouts possible from 4Q26.","Phase 2 investigator-initiated trial in M. abscessus lung disease enrollment expected 1Q26; topline late 2027.","Phase 1 first-in-human trial of AN2-502998 for Chagas nearing completion; initial data expected 1Q26."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110487,"accession_number":"0001193125-26-099169","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"AN2 Therapeutics announces $40M private placement of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$40M from sale of 8.25M shares at $2.85/share and 5.79M pre-funded warrants at $2.84999/warrant.","Investors include Coastlands Capital, Commodore Capital, Vivo Capital; Leerink Partners as placement agent.","Pre-funded warrants have $0.00001 exercise price, exercisable immediately, subject to 9.99% beneficial ownership blocker.","Closing expected March 10, 2026; resale registration statement to be filed within 30 days after closing.","Net proceeds for general corporate purposes and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110486,"accession_number":"0001193125-26-029540","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AN2 Therapeutics names Sarah Williams as VP, Controller and PAO; CFO Lucy Day salary reduced from Apr 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sarah Williams appointed VP, Controller and Principal Accounting Officer, effective Feb 1, 2026.","Lucy Day remains CFO; base salary reduced to $223,600 from April 1, 2026 (current $335,400 until Mar 31).","Williams receives annual base salary of $310,000 with target annual bonus of 30% of base.","Day's severance eligibility reduced to 50% of plan if terminated after April 1, 2026 (non-CIC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127097,"accession_number":"0001193125-25-277662","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics Q3 2025 net loss $9.4M, cash $65.1M; Chagas Phase 1 ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.4M vs $12.7M in Q3 2024, R&D expense $7.0M (down from $8.3M), G&A $3.0M.","Cash, equivalents and investments $65.1M at Sept 30, 2025; projected runway into 2028.","Chagas Phase 1 of oral AN2-502998 advancing; data expected Q1 2026, Phase 2 start in 2026.","M. abscessus program: IIT expected to begin enrollment early 2026, pending regulatory clearance.","Collaboration with GSK on boron-based TB drugs, with third-year Gates Foundation funding."],"consensus_eps_estimate":-0.2244,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143890,"accession_number":"0000950170-25-107278","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics Q2 net loss narrows to $6.5M; Chagas Phase 1 dosing underway; cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.5M vs $14.4M in Q2 2024; R&D expenses down to $3.2M from $12.1M.","Cash, cash equivalents, and investments of $71.2M; operations funded into 2028.","Phase 1 FIH trial for Chagas drug AN2-502998 dosing started; Phase 2 planned for 2026.","Melioidosis observational study showed ~40% 90-day mortality; seeking U.S. government funding for Phase 2.","Two oncology development candidates (ENPP1 and PI3Kα) expected within 12 months."],"consensus_eps_estimate":-0.3397,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162168,"accession_number":"0001193125-25-143187","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"AN2 Therapeutics exchanges 2.8M common shares for pre-funded warrants with Coastlands Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 2,500,000 shares of common stock for pre-funded warrant for 2,500,000 shares on June 17, 2025.","Exchanged additional 300,000 shares for pre-funded warrant for 300,000 shares on June 19, 2025.","Warrants have $0.00001 exercise price, no expiration, and beneficial ownership blocker at 9.99% (up to 19.99%).","Issued under Section 3(a)(9) exemption from registration; form of warrant filed as Exhibit 4.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162167,"accession_number":"0001193125-25-138796","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AN2 Therapeutics posts updated investor presentation with no new material facts","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed 8-K under Item 7.01 furnishing an updated investor presentation dated June 2025.","No specific financial results, pipeline updates, or guidance changes disclosed in the filing.","Presentation available on the 'Investors' section of the company's website.","No material information beyond the routine investor update was provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162166,"accession_number":"0001193125-25-127595","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AN2 Therapeutics stockholders elect three Class III directors and ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eric Easom, Stephanie Wong, and Joseph Zakrzewski elected as Class III directors for term expiring 2028.","Easom received 13,983,213 votes for; Wong 10,584,641; Zakrzewski 10,928,200; each had 3,403,334 broker non-votes.","Ratification of PricewaterhouseCoopers LLP as independent auditor passed with 23,736,942 votes for, 47,413 against, 144,085 abstentions.","Approximately 79.50% of outstanding shares (23,928,440) represented at the meeting, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162165,"accession_number":"0000950170-25-070305","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports Q1 2025 net loss of $10.6M; cash runway extended to 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.6M vs $16.6M in Q1 2024; R&D expenses down to $7.7M from $14.7M.","Cash and investments of $78.5M at March 31, 2025; operating runway now projected into 2028.","Initiated Phase 1 first-in-human study of AN2-502998 for chronic Chagas disease; expected completion in H2 2025.","Plans to initiate Phase 2 study of epetraborole in melioidosis; advancing epetraborole for NTM lung disease non-dilutive.","Oncology pipeline advancing; first compound(s) expected to enter development in 2025 within current cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162164,"accession_number":"0001193125-25-110019","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AN2 Therapeutics Phase 3 EBO-301 misses primary endpoint; outlines boron pipeline milestones, cash runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 portion of EBO-301 (n=97) did not meet primary endpoint of QOL-B respiratory domain improvement at month 6.","Cash, cash equivalents & investments $78.5M as of March 31, 2025; cash runway extended into 2028.","Initiated start up for Phase 1 study of AN2-502998 for chronic Chagas disease, expected completion in 2H25.","Plans Phase 2 study for epetraborole in melioidosis in 2H25 aiming to reduce ~40% mortality.","First oncology compounds from boron platform on track for development in 2H25, targeting ENPP1, PI3Kα."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180169,"accession_number":"0000950170-25-044353","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports FY2024 net loss $51.3M; Phase 3 epetraborole data expected 2Q25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, investments $88.6M at Dec 31, 2024; expected to fund operations through 2027.","FY2024 net loss $51.3M vs $64.7M prior year; Q4 net loss $7.5M vs $16.9M.","Phase 3 topline data for epetraborole in treatment-refractory MAC lung disease due 2Q25.","Phase 1 trial of AN2-502998 for Chagas disease to start mid-2025 in healthy volunteers.","First oncology candidate from boron chemistry platform on track to advance in 2H25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196955,"accession_number":"0000950170-24-126276","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports Q3 2024 net loss $12.7M, positive Phase 2 epetraborole PRO data in TR-MAC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.7M in Q3 2024 vs $16.7M in Q3 2023; cash $93.4M, expected to fund operations through 2027.","Phase 2 portion of EBO-301: epetraborole achieved nominally significant improvements in QOL-B (p=0.0365) and MACrO2 (p=0.0433) vs placebo.","Company plans to meet FDA in H1 2025 to discuss reinitiating Phase 3 TR-MAC study and top-line Phase 3 data in mid-2025.","Achieved 50% reduction in expenditures through strategic realignment; R&D expenses decreased to $8.3M from $14.4M.","Advancing boron chemistry pipeline: Chagas Phase 1 mid-2025, melioidosis Phase 2 enrollment H2 2025, and Gates Foundation grant."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196954,"accession_number":"0001193125-24-251240","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AN2 Therapeutics appoints Joshua Eizen as Chief Legal Officer and COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua Eizen appointed Chief Legal Officer and Chief Operating Officer effective Nov 4, 2024.","Salary increased to $450,000; granted option for 63,000 shares and 31,500 RSUs.","Option vests monthly over 48 months; RSUs vest annually over 4 years.","Eizen previously served as Chief Legal Counsel; no family relationships or related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213241,"accession_number":"0001193125-24-202430","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"AN2 Therapeutics adopts limited-duration stockholder rights plan after BML accumulates 19.3% stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights plan triggered by rapid accumulation of 19.3% of ANTX common stock by BML Investment Partners, as disclosed in Aug. 14, 2024 13G/A filing.","One preferred stock purchase right distributed per common share held on Aug. 29, 2024; exercise price $6.50 per one-thousandth of Series A Preferred.","Rights become exercisable if a person or group acquires 20% or more of common stock (including synthetic ownership).","Rights expire Aug. 15, 2025, unless earlier redeemed ($0.01 per right) or exchanged by Board.","Plan designed to protect all stockholders and prevent coercive takeover tactics without paying a control premium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213240,"accession_number":"0000950170-24-096173","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports Q2 net loss $14.4M; terminates epetraborole Phase 2/3 trial in TR-MAC lung disease","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments $104.5M at June 30, 2024; runway through 2027.","Net loss $14.4M in Q2 2024 vs $15.8M in Q2 2023; R&D $12.1M, G&A $3.7M.","Terminated Phase 2/3 EBO-301 trial after sputum culture conversion at Month 6 similar between arms; PRO tool validated.","Plans to advance AN2-502998 into Phase 1 for Chagas disease in 2025 and epetraborole into Phase 2 for melioidosis.","Published study on epetraborole efficacy against M. abscessus mouse lung infection model in Antimicrobial Agents and Chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213239,"accession_number":"0001193125-24-197047","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.05","5.02","7.01","8.01","9.01"],"status":"ready","headline":"AN2 discontinues EBO-301 MAC lung study, cuts ~50% workforce, shifts pipeline focus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2/3 EBO-301 study discontinued; sputum culture conversion at Month 6: 13.2% vs 10.0% (p=0.64).","Reduction in force of ~50% of employees; expects $2-3M in severance charges.","CMO Paul Eckburg departs Aug 30, 2024; will continue as consultant with vesting.","Company shifts focus to boron chemistry platform; plans Phase 1 for Chagas, Phase 2 for melioidosis.","Cost savings expected to extend cash runway through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232401,"accession_number":"0001193125-24-166938","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"AN2 Therapeutics shareholders elect directors, ratify PwC, approve officer exculpation amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["78.31% quorum with 23,360,239 shares represented; all three Class II director nominees elected.","Margaret FitzPatrick, Patricia Martin, Melvin Spigelman each received over 17.7M votes for.","PricewaterhouseCoopers LLP ratified as auditor: 23,344,330 for, 12,786 against.","Amendment to certificate of incorporation for officer exculpation approved: 18,416,318 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232400,"accession_number":"0000950170-24-059527","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics Q1 net loss $16.6M; Phase 2 TR-MAC data expected August 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.6M for Q1 2024 vs $15.3M in Q1 2023; cash $118.1M.","R&D spend $14.7M, up from $12.0M YoY; G&A $3.6M, down from $4.1M.","Phase 3 enrollment paused Feb 2024 due to blinded aggregate efficacy signal; no safety issues.","97 patients remain in Phase 3; topline Phase 2 data from EBO-301 due August 2024.","Epetraborole targets treatment-refractory MAC lung disease with high unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250680,"accession_number":"0000950170-24-038055","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports FY2023 net loss of $64.7M; Phase 2/3 trial paused, topline expected summer 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss FY2023 $64.7M vs $41.0M prior year; Q4 net loss $16.9M vs $11.8M.","Cash, equivalents and investments $134.5M at Dec 31, 2023.","Phase 3 enrollment in epetraborole TR-MAC trial paused voluntarily Feb 2024 due to potentially lower efficacy; Phase 2 topline results expected summer 2024.","Plan to discuss Phase 2/3 data with FDA; no safety concerns prompted pause.","Executed license from UGA for Chagas disease candidate AN2-502998; Gates Foundation grant for TB/malaria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250679,"accession_number":"0001193125-24-031008","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AN2 Therapeutics pauses Phase 3 enrollment in epetraborole trial after efficacy concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary pause of Phase 3 enrollment in EBO-301 trial for treatment-refractory MAC lung disease.","Blinded aggregate analysis showed potentially lower than expected efficacy; no safety concerns cited.","Phase 2 part completed enrollment with 80 patients; Phase 3 had enrolled nearly 100 patients to date.","Enrolled patients allowed to continue; topline Phase 2 data expected summer 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268211,"accession_number":"0000950170-23-062046","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics Q3 net loss $16.7M; epetraborole Phase 3 enrollment underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.7M for Q3 2023, up from $11.3M in Q3 2022; R&D and G&A expenses increased.","Cash and investments $150.2M at Sept 30; $70M raised in August stock offering; cash runway through summer 2025.","Phase 3 part of pivotal epetraborole trial in refractory MAC lung disease initiated; Phase 2 top-line data expected summer 2024.","Received Bill & Melinda Gates Foundation grant for TB/malaria; exclusive license for Chagas disease candidate AN2-502998."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285433,"accession_number":"0001193125-23-233934","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AN2 Therapeutics starts Phase 3 trial for epetraborole in refractory MAC lung disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 enrollment completed with 80 patients; topline Phase 2 data expected summer 2024.","Phase 3 part launched with over 100 sites in U.S., Japan, South Korea, Australia; plans to enroll ~230 patients.","Epetraborole is an oral, once-daily drug; FDA granted Fast Track, QIDP, and orphan drug designations.","No approved oral therapy currently exists for MAC lung disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285432,"accession_number":"0001193125-23-230786","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AN2 Therapeutics appoints CFO Lucy Day as Principal Accounting Officer; VP Controller departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucy Day, current CFO, adds role of Principal Accounting Officer effective September 1, 2023.","Michael Nazak, Vice President & Corporate Controller, to depart on September 15, 2023.","Annie Yoshiyama hired as new Vice President, Finance and Corporate Controller."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285431,"accession_number":"0001193125-23-214362","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"AN2 Therapeutics prices $70M underwritten offering of 7.8M shares at $9.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 7,777,778 shares at $9.00/share, gross proceeds ~$70M.","Investors include RA Capital, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital, Avidity Partners, Janus Henderson, Surveyor Capital.","Expected close on Aug 18, 2023; Cowen, Leerink, Evercore as book-runners.","Offering priced at premium to closing price; sold under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285430,"accession_number":"0000950170-23-041358","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics Q2 net loss $15.8M; expects Phase 2 enrollment completion and Phase 3 start in Sep 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.8M for Q2 2023 vs $10.1M prior year; R&D expenses increased on clinical trial costs.","Cash, cash equivalents and investments $95.3M at June 30, 2023, after ATM offering of 2.5M shares at $8.00.","Phase 2 portion of pivotal epetraborole study for treatment-refractory MAC lung disease enrollment to finish in August; Phase 3 begins September.","Top-line Phase 2 data expected summer 2024; over 90 active clinical sites across U.S., Japan, South Korea, Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305304,"accession_number":"0001193125-23-164459","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AN2 Therapeutics stockholders elect three Class I directors and ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Kabeer Aziz (14.78M for), Gilbert Lynn Marks (14.78M for), and Rob Readnour (14.61M for) as Class I directors.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2023: 16.56M for, 51.6K against.","Quorum of 16,610,548 shares (85.5% of outstanding) present at June 7, 2023 annual meeting.","Results based on proxy statement filed April 26, 2023; no other proposals voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305303,"accession_number":"0000950170-23-021275","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports Q1 net loss of $15.3M; Phase 2/3 trial enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.3M for Q1 2023, compared to $7.7M in Q1 2022.","R&D expenses $12.0M (up from $5.6M); G&A expenses $4.1M (up from $2.1M).","Cash, cash equivalents and investments totaled $88.5M at March 31, 2023.","Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease.","Expects to complete Phase 2 enrollment mid-2023; top-line data ~9 months after enrollment completion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324754,"accession_number":"0000950170-23-010615","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports Q4 2022 net loss $11.8M, full year loss $41.0M; cash $99.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2022 was $11.8M and full year 2022 was $41.0M.","R&D expenses for full year 2022 were $29.5M vs $16.9M in 2021; G&A $12.8M vs $4.7M.","Cash, cash equivalents and investments totaled $99.3M at Dec 31, 2022, expected to fund through mid-2024.","Phase 2/3 pivotal trial for epetraborole in MAC lung disease approaching 60 sites; Phase 2 enrollment expected to complete mid-2023.","Awarded up to $17.8M NIAID contract to develop epetraborole for melioidosis using non-dilutive funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342564,"accession_number":"0000950170-22-023882","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics Q3 2022: Cash $106.4M; ongoing epetraborole trial; NIAID contract up to $17.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments totaled $106.4M as of Sep 30, 2022; expected to fund operations through mid-2024.","R&D expenses increased vs. Q3 2021 due to license fee, clinical activity, and personnel costs.","Enrollment ongoing in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; Phase 2 top-line data expected ~9 months after enrollment completion.","Awarded up to $17.8M NIAID contract to develop epetraborole for acute systemic melioidosis.","Phase 1 study in Japanese subjects supports 500mg once-daily dose regardless of ADH genotype."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342563,"accession_number":"0001193125-22-258534","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AN2 Therapeutics updates epetraborole development; Phase 1 Japan study supports 500 mg dose; EU orphan designation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 study in Japanese volunteers (EBO-103) showed no adverse events, supports once-daily 500 mg dose for Phase 2/3.","Epetraborole exposures similar across ADH genotypes and consistent with prior Phase 1 study in non-Japanese subjects.","EU Commission granted orphan medicinal product designation for epetraborole in NTM lung disease.","Company plans to initially focus clinical development for treatment-refractory MAC lung disease on Japan and the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359248,"accession_number":"0000950170-22-016887","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports Q2 2022 cash of $115.8M, updates on epetraborole trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $115.8M at June 30, 2022; sufficient to fund operations through mid-2024.","Enrolling U.S. patients in Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; topline Phase 2 results expected mid-2023.","Completed Phase 1 PK/safety study in Japan; gained PMDA alignment on microbiological primary endpoint for potential registration.","Maggie FitzPatrick appointed to Board of Directors; she previously led public affairs at Johnson & Johnson.","R&D and G&A expenses increased due to higher trial activity and expanded post-IPO operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378061,"accession_number":"0001193125-22-185058","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AN2 screens first patient in pivotal Phase 2/3 trial of epetraborole for refractory MAC lung disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Epetraborole is a once-daily oral therapy with novel MOA for treatment-refractory MAC lung disease, the most common NTM lung disease.","Phase 2/3 adaptive trial (EBO-301) targets ~314 patients; Phase 2 topline expected mid-2023, Phase 3 mid-2024.","Epetraborole has FDA QIDP, Fast Track, and Orphan Drug designations; plans to use LPAD pathway for streamlined approval.","First patient screened; Phase 2 will assess clinical response, safety, and PK to inform Phase 3 design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378060,"accession_number":"0000950170-22-008992","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AN2 Therapeutics reports Q1 2022 results, cash $118.4M; progresses epetraborole clinical program","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Cash and investments total $118.4M as of March 31, 2022; expects operating runway through mid-2024.","Upsized IPO raised $79.4M; full exercise of underwriter option added $10.4M in April.","Phase 2/3 trial enrollment for treatment-refractory MAC lung disease expected to begin H1 2022.","FDA cleared IND, granted Fast Track, QIDP, and orphan drug designation for epetraborole.","Appointed Dr. Mel Spigelman and Maggie FitzPatrick to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378059,"accession_number":"0001193125-22-145000","cik":1880438,"company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AN2 Therapeutics appoints Maggie FitzPatrick as Class II director with option grant and cash retainer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed May 5, 2022; also joins nominating and corporate governance committee.","Initial stock option grant with grant-date value of $209,093 vesting monthly over 3 years.","Annual cash director retainer of $39,000 paid quarterly for board and committee service.","FitzPatrick brings experience from Johnson & Johnson, Cigna, and Exelon; also serves on VistaGen board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":167114982.60043195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}